The New England journal of medicine
-
Comment Letter
Case 23-2013: a 54-year-old woman with metformin toxicity.
-
Randomized Controlled Trial Multicenter Study
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.
The efficacy of autologous stem-cell transplantation during the first remission in patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate risk or high risk on the International Prognostic Index remains controversial and is untested in the rituximab era. ⋯ Early autologous stem-cell transplantation improved progression-free survival among patients with high-intermediate-risk or high-risk disease who had a response to induction therapy. Overall survival after transplantation was not improved, probably because of the effectiveness of salvage transplantation. (Funded by the National Cancer Institute, Department of Health and Human Services, and others; SWOG-9704 ClinicalTrials.gov number, NCT00004031.).
-
Comment Letter
Case 23-2013: a 54-year-old woman with metformin toxicity.